Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 6/2011

01-12-2011 | Rheumatic Manifestations of Other Diseases (Roland Staud, Section Editor)

Evidence for Shared Pain Mechanisms in Osteoarthritis, Low Back Pain, and Fibromyalgia

Author: Roland Staud

Published in: Current Rheumatology Reports | Issue 6/2011

Login to get access

Abstract

Osteoarthritis (OA), low back pain (LBP), and fibromyalgia (FM) are common chronic pain disorders that occur frequently in the general population. They are a significant cause of dysfunction and disability. Why some of these chronic pain disorders remain localized to few body areas (OA and LBP), whereas others become widespread (FM) is unclear at this time. Genetic, environmental, and psychosocial factors likely play an important role. Although patients with OA, LBP, and FM frequently demonstrate abnormalities of muscles, ligaments, or joints, the severity of such changes is only poorly correlated with clinical pain. Importantly, many patients with these chronic pain disorders show signs of central sensitization and abnormal endogenous pain modulation. Nociceptive signaling is actively regulated by the central nervous system to allow adaptive responses after tissue injuries. Thus, abnormal processing of tonic peripheral tissue impulse input likely plays an important role in the pathogenesis of OA, LBP, or FM. Tonic and/or intense afferent nociceptive barrage can result in central sensitization that depends on facilitatory input from brainstem centers via descending pain pathways to the spinal cord. Abnormal endogenous control of these descending pathways can lead to excessive excitability of dorsal horn neurons of the spinal cord and pain. Ineffective endogenous pain control and central sensitization are important features of OA, LBP, and FM patients.
Literature
1.
Dubner R. Neuronal plasticity and pain following peripheral tissue inflammation or nerve injury. In: Bond M, Charlton E, Woolf CJ, editors. Proceedings of Vth World Congress on Pain. Pain Research and Clinical Management. Amsterdam: Elsevier; 1991. p. 263–76.
2.
Price DD. Characterizing central mechanisms of pathological pain states by sensory testing and neurophysiological analysis. In: Casey KL, editor. Pain and central nervous system disease: mechanisms and assessment. New York: Raven; 1991. p. 103–15.
3.
Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993;52:259–85.PubMedCrossRef
4.
O’Neill S, Manniche C, Graven-Nielsen T, Arendt-Nielsen L. Generalized deep-tissue hyperalgesia in patients with chronic low-back pain. Eur J Pain. 2007;11:415–20.PubMedCrossRef
5.
Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell I, et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum. 2009;61:1226–34.PubMedCrossRef
6.
Staud R. Is it all central sensitization? Role of peripheral tissue nociception in chronic musculskeletal pain. Curr Rheumatol Rep. 2010;12:448–54.PubMedCrossRef
7.
Hoheisel U, Mense S, Simons DG, Yu XM. Appearance of new receptive fields in rat dorsal horn neurons following noxious stimulation of skeletal muscle: a model for referral of muscle pain. Neurosci Lett. 1993;153:9–12.PubMedCrossRef
8.
Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. Rheum Dis Clin North Am. 2009;35:263–74.PubMedCrossRef
9.
Simone DA, Marchettini P, Caputi G, Ochoa JL. Identification of muscle afferents subserving sensation of deep pain in humans. J Neurophysiol. 1994;72:883–9.PubMed
10.
Rang HP, Bevan S, Dray A. Chemical activation of nociceptive peripheral neurones. Br Med Bull. 1991;47:534–48.PubMed
11.
Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol. 1992;38:397–421.PubMedCrossRef
12.
Liang YF, Haake B, Reeh PW. Sustained sensitization and recruitment of rat cutaneous nociceptors by bradykinin and a novel theory of its excitatory action. J Physiol. 2001;532:229–39.PubMedCrossRef
13.
14.
Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44:293–9.PubMedCrossRef
15.
Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26:1235–8.PubMedCrossRef
16.
Brennan LK, Harte BH, Fitzgerald DJ, McCrory CR. Surgery induces cyclooxygenase-2 expression in the rat cervical spinal cord. Reg Anesth Pain Med. 2009;34:549–52.PubMedCrossRef
17.
Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410:471–5.PubMedCrossRef
18.
Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24:8494–9.PubMedCrossRef
19.
Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959–64.PubMedCrossRef
20.
Fields HL, Basbaum AI. Central nervous system mechanisms of pain modulation. In: Wall PD, Melzack R, editors. Textbook of pain. 4th ed. Edinburgh: Churchill Livingstone; 1999. p. 309–29.
21.
22.
Urban MO, Jiang MC, Gebhart GF. Participation of central descending nociceptive facilitatory systems in secondary hyperalgesia produced by mustard oil. Brain Res. 1996;737:83–91.PubMedCrossRef
23.
24.
Benarroch EE. Descending monoaminergic pain modulation—bidirectional control and clinical relevance. Neurology. 2008;71:217–21.PubMedCrossRef
25.
Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci. 2004;25:613–7.PubMedCrossRef
26.
Rakic P. Neurogenesis in adult primate neocortex: an evaluation of the evidence. Nat Rev Neurosci. 2002;3:65–71.PubMedCrossRef
27.
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895–926.PubMedCrossRef
28.
Mendell LM. Physiological properties of unmyelinated fiber projection to the spinal cord. Exp Neurol. 1966;16:316–32.PubMedCrossRef
29.
Price DD, Hu JW, Dubner R, Gracely RH. Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain. 1977;3:57–68.PubMedCrossRef
30.
31.
32.
Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705.PubMedCrossRef
33.
Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain. 2000;4:5–15.PubMedCrossRef
34.
Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev. 2009;60:214–25.PubMedCrossRef
35.
Tracey I, Dunckley P. Importance of anti- and pro-nociceptive mechanisms in human disease. Gut. 2004;53:1553–5.PubMedCrossRef
36.
Mayer DJ, Wolfle TL, Akil H, Carder B, Liebeskind JC. Analgesia from electrical stimulation in the brainstem of the rat. Science. 1971;174:1351–4.PubMedCrossRef
37.
Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol. 2000;27:1513–7.PubMed
38.
Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet. 2005;365:965–73.PubMedCrossRef
39.
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–99.PubMedCrossRef
40.
Levine JD, Dardick SJ, Basbaum AI, Scipio E. Reflex neurogenic inflammation. I. Contribution of the peripheral nervous system to spatially remote inflammatory responses that follow injury. J Neurosci. 1985;5:1380–6.PubMed
41.
Chahl LA, Ladd RJ. Local oedema and general excitation of cutaneous sensory receptors produced by electrical stimulation of the saphenous nerve in the rat. Pain. 1976;2:25–34.PubMedCrossRef
42.
Schaible HG, Schmidt RF, Willis WD. Convergent inputs from articular, cutaneous and muscle receptors onto ascending tract cells in the cat spinal cord. Exp Brain Res. 1987;66:479–88.PubMedCrossRef
43.
Yu XM, Mense S. Response properties and descending control of rat dorsal horn neurons with deep receptive fields. Neuroscience. 1990;39:823–31.PubMedCrossRef
44.
Szebenyi B, Hollander AP, Dieppe P, Quilty B, Duddy J, Clarke S, et al. Associations between pain, function, and radiographic features in osteoarthritis of the knee. Arthritis Rheum. 2006;54:230–5.PubMedCrossRef
45.
Creamer P, Lethbridge-Cejku M, Hochberg MC. Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures. J Rheumatol. 1999;26:1785–92.PubMed
46.
•• Arendt-Nielsen L, Nie HL, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, et al. Sensitization in patients with painful knee osteoarthritis. Pain. 2010;149:573–81. OA patients showed facilitation of temporal summation from both the knee and tibialis anterior muscle and had significantly less pain inhibition compared with controls. No correlations were found between standard radiological findings and clinical/experimental pain parameters.PubMedCrossRef
47.
Bingham III CO, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54:3494–507.PubMedCrossRef
48.
Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001;134:541–9.PubMed
49.
Sowers MF, Hayes C, Jamadar D, Capul D, Lachance L, Jannausch M, et al. Magnetic resonance-detected subchondral bone marrow and cartilage defect characteristics associated with pain and X-ray-defined knee osteoarthritis. Osteoarthr Cartil. 2003;11:387–93.PubMedCrossRef
50.
Hunter DJ, March L, Sambrook PN. The association of cartilage volume with knee pain. Osteoarthr Cartil. 2003;11:725–9.PubMedCrossRef
51.
Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8:R21.PubMedCrossRef
52.
Kornaat PR, Bloem JL, Ceulemans RY, Riyazi N, Rosendaal FR, Nelissen RG, et al. Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology. 2006;239:811–7.PubMedCrossRef
53.
Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep. 2006;8:37–44.PubMedCrossRef
54.
55.
O’Driscoll SL, Jayson MI. Pain threshold analysis in patients with osteoarthrosis of hip. Br Med J. 1974;3:714–5.PubMedCrossRef
56.
•• Gwilym SE, Fillipini N, Douaud G, Carr AJ, Tracey I. Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty: a longitudinal voxel-based-morphometric study. Arthritis Rheum. 2010;62:2930–40. This work shows that thalamic atrophy of OA patients reverses after hip arthroplasty and is associated with decreased pain and increased function.PubMedCrossRef
57.
Kosek E, Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain. 2000;4:229–38.PubMedCrossRef
58.
59.
Hestbaek L, Leboeuf-Yde C, Engberg M, Lauritzen T, Bruun NH, Manniche C. The course of low back pain in a general population. Results from a 5-year prospective study. J Manip Physiol Ther. 2003;26:213–9.CrossRef
60.
Hestbaek L, Leboeuf-Yde C, Manniche C. Low back pain: what is the long-term course? A review of studies of general patient populations. Eur Spine J. 2003;12:149–65.PubMed
61.
Wilder-Smith OHG, Tassonyi E, Arendt-Nielsen L. Preoperative back pain is associated with diverse manifestations of central neuroplasticity. Pain. 2002;97:189–94.PubMedCrossRef
62.
Giesecke T, Gracely RH, Grant MAB, Nachemson A, Petzke F, Williams DA, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum. 2004;50:613–23.PubMedCrossRef
63.
Peters M. Disturbances in pain perception in chronic back pain. In: Lautenbacher S, Fillingim RB, editors. Pathophysiology of pain perception. New York: Kluwer Academic/Plenum; 2004. p. 59–76.CrossRef
64.
Arendt-Nielsen L, Graven-Nielsen T, Svensson P. Disturbances of pain perception in myofascial pain syndrome and other musculoskeletal pains. In: Lautenbacher S, Fillingim RB, editors. Pathophysiology of pain perception. New York: Kluwer Academic/Plenum; 2004. p. 93–106.CrossRef
65.
• Staud R, Robinson ME, Weyl EE, Price DD. Pain variability in fibromyalgia is related to activity and rest: role of peripheral tissue impulse input. J Pain. 2010;11:1376–83. Alternating strenuous exercise with brief rest periods not only decreased overall clinical pain in FM patients but also their mechanical hyperalgesia. No prolonged worsening of overall FM pain and hyperalgesia occurred despite vigorous muscle activity. These findings contribute further evidence that FM pain and hyperalgesia are at least partially maintained by muscle impulse input, and that some types of exercises may be beneficial for FM.PubMedCrossRef
66.
Bajaj P, Bajaj P, Graven-Nielsen T, Arendt-Nielsen L. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain. 2001;93:107–14.PubMedCrossRef
67.
Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 2003;48:1420–9.PubMedCrossRef
68.
Flor H, Diers M, Birbaumer N. Peripheral and electrocortical responses to painful and non-painful stimulation in chronic pain patients, tension headache patients and healthy controls. Neurosci Lett. 2004;361:147–50.PubMedCrossRef
69.
Kleinbohl D, Holzl R, Moltner A, Rommel C, Weber C, Osswald PM. Psychophysical measures of sensitization to tonic heat discriminate chronic pain patients. Pain. 1999;81:35–43.PubMedCrossRef
70.
Clauw DJ, Williams D, Lauerman W, Dahlman M, Aslami A, Nachemson AL, et al. Pain sensitivity as a correlate of clinical status in individuals with chronic low back pain. Spine. 1999;24:2035–41.PubMedCrossRef
71.
Flor H, Braun C, Elbert T, Birbaumer N. Extensive reorganization of primary somatosensory cortex in chronic back pain patients. Neurosci Lett. 1997;224:5–8.PubMedCrossRef
72.
Coderre TJ. Spinal cord mechanisms of hyperalgesia and allodynia. In: Bushnell MC, Basbaum AI, editors. Pain. San Diego: Academic; 2008. p. 339–80.
73.
Severeijns R, Vlaeyen JW, Van den Hout MA, Weber WE. Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. Clin J Pain. 2001;17:165–72.PubMedCrossRef
74.
Macfarlane GJ, Morris S, Hunt IM, Benjamin S, McBeth J, Papageorgiou AC, et al. Chronic widespread pain in the community: the influence of psychological symptoms and mental disorder on healthcare seeking behavior. J Rheumatol. 1999;26:413–9.PubMed
75.
Papageorgiou AC, Macfarlane GJ, Thomas E, Croft PR, Jayson MI, Silman AJ. Psychosocial factors in the workplace—do they predict new episodes of low back pain? Evidence from the South Manchester Back Pain Study. Spine. 1997;22:1137–42.PubMedCrossRef
76.
Mannion AF, Dolan P, Adams MA. Psychological questionnaires: do “abnormal” scores precede or follow first-time low back pain? Spine. 1996;21:2603–11.PubMedCrossRef
77.
Burckhardt CS, Clark SR, Campbell SM, O’Reilly CA, Bennett RM. Events and co-morbidities associated with the onset of fibromyalgia. J Musuculoskel Pain. 1995;3:71.
78.
Staud R, Robinson ME, Price DD. Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain. 2007;8:893–901.PubMedCrossRef
79.
Gibson SJ, Littlejohn GO, Gorman MM, Helme RD, Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994;58:185–93.PubMedCrossRef
80.
Lautenbacher S, Rollman GB, McCain GA. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain. 1994;59:45–53.PubMedCrossRef
81.
Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain. 1996;68:375–83.PubMedCrossRef
82.
Perrot S, Dickenson AH, Bennett RM. Fibromyalgia: harmonizing science with clinical practice considerations. Pain Pract. 2008;8:177–89.PubMedCrossRef
83.
Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999;26:1564–9.PubMed
84.
Staud R, Craggs JG, Perlstein WM, Robinson ME, Price DD. Brain activity associated with slow temporal summation of C-fiber evoked pain in fibromyalgia patients and healthy controls. Eur J Pain. 2008;12:1078–89.PubMedCrossRef
85.
Staud R, Price DD, Robinson ME, Mauderli AP, Vierck CJ. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain. 2004;110:689–96.PubMedCrossRef
86.
Russell IJ, Bieber CS. Myofascial pain and fibromyalgia syndrome. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack’s textbook of pain. 5th ed. Phildelphia: Elsevier Churchill Livingstone; 2006. p. 669–81.
87.
Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain. 2000;87:201–11.PubMedCrossRef
88.
89.
Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci. 2002;25:319–25.PubMedCrossRef
90.
Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Brain Res Rev. 2004;46:295–309.PubMedCrossRef
91.
Ren K, Dubner R. Descending control mechanisms. In: Bushnell MC, Basbaum AI, editors. Pain. San Diego: Academic; 2008. p. 723–62.
92.
93.
94.
Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550–6.PubMedCrossRef
95.
Staud R, Robinson ME, Vierck CJ, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain. 2003;101:167–74.PubMedCrossRef
96.
Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997;70:41–51.PubMedCrossRef
97.
Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13:189–96.PubMedCrossRef
98.
Melzack R, Coderre TJ, Katz J, Vaccarino AL. Central neuroplasticity and pathological pain. Ann N Y Acad Sci. 2001;933:157–74.PubMedCrossRef
99.
Vierck Jr CJ. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain. 2006;124:242–63.PubMedCrossRef
100.
Arendt-Nielsen L, Henriksson KG. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition. Best Pract Res Clin Rheumatol. 2007;21:465–80.CrossRef
101.
Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. Idiopathic pain disorders—pathways of vulnerability. Pain. 2006;123:226–30.PubMedCrossRef
102.
Yunus MB. Central sensitivity syndromes: an overview. J Musculoskelet Pain. 2009;17:400–8.CrossRef
103.
Plesh O, Wolfe F, Lane N. The relationship between fibromyalgia and temporomandibular disorders: prevalence and symptom severity. J Rheumatol. 1996;23:1948–52.PubMed
104.
Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3541–6.PubMedCrossRef
105.
Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points. Arthritis Rheum. 1983;26:817–24.PubMedCrossRef
106.
Okifuji A, Turk DC, Marcus DA. Comparison of generalized and localized hyperalgesia in patients with recurrent headache and fibromyalgia. Psychosom Med. 1999;61:771–80.PubMed
107.
Marcus DA. Duloxetine use in painful conditions. Expert Opinion on Pharmacotherapy. 2011;12:1333–40.PubMedCrossRef
Metadata
Title
Evidence for Shared Pain Mechanisms in Osteoarthritis, Low Back Pain, and Fibromyalgia
Author
Roland Staud
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 6/2011
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-011-0206-6

Other articles of this Issue 6/2011

Current Rheumatology Reports 6/2011 Go to the issue

Rheumatic Manifestations of Other Diseases (Roland Staud, Section Editor)

Recent Advances in the Understanding of Genetic Susceptibility to Chronic Pain and Somatic Symptoms

VASCULITIS (LUIS R. ESPINOZA, SECTION EDITOR)

The Clinical and Pathological Features of IgG4-Related Disease

VASCULITIS (LUIS R. ESPINOZA, SECTION EDITOR)

Vasculitides Throughout History and Their Clinical Treatment Today

Vasculitis (Luis R. Espinoza, Section Editor)

Vasculitis in Sjögren’s Syndrome

VASCULITIS (LUIS R. ESPINOZA, SECTION EDITOR)

Neuromyelitis Optica-AQP4: An Update

VASCULITIS (LUIS R. ESPINOZA, SECTION EDITOR)

HIV Infection and Clinical Spectrum of Associated Vasculitides
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits